Trials / Completed
CompletedNCT02436239
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 7 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vilazodone | Vilazodone tablets, once daily, oral administration |
Timeline
- Start date
- 2015-05-02
- Primary completion
- 2018-07-23
- Completion
- 2018-07-23
- First posted
- 2015-05-06
- Last updated
- 2019-09-11
- Results posted
- 2019-09-11
Locations
56 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02436239. Inclusion in this directory is not an endorsement.